Pyrazolo-Pyrimidines: A Novel Heterocyclic Scaffold for Potent and Selective p38alpha Inhibitors
Journal Article
·
· BioOrganic and Medicinal Chemistry Letters
The synthesis and structure-activity relationships (SAR) of p38a MAP kinase inhibitors based on a pyrazolo-pyrimidine scaffold are described. These studies led to the identification of compound 2x as a potent and selective inhibitor of p38a MAP kinase with excellent cellular potency toward the inhibition of TNFa production. Compound 2x was highly efficacious in vivo in inhibiting TNFa production in an acute murine model of TNFa production. X-ray co-crystallography of a pyrazolo-pyrimidine analog 2b bound to unphosphorylated p38a is also disclosed.
- Research Organization:
- Brookhaven National Laboratory (BNL) National Synchrotron Light Source
- Sponsoring Organization:
- Doe - Office Of Science
- DOE Contract Number:
- AC02-98CH10886;
- OSTI ID:
- 959850
- Report Number(s):
- BNL-82836-2009-JA
- Journal Information:
- BioOrganic and Medicinal Chemistry Letters, Journal Name: BioOrganic and Medicinal Chemistry Letters Vol. 18
- Country of Publication:
- United States
- Language:
- English
Similar Records
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 2
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2
Journal Article
·
Wed Nov 20 00:00:00 UTC 2013
· Bioorg. Med. Chem. Lett.
·
OSTI ID:1025622
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors
Journal Article
·
Fri Nov 19 00:00:00 UTC 2010
· Bioorg. Med. Chem. Lett.
·
OSTI ID:1006183
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2
Journal Article
·
Mon Jun 30 00:00:00 UTC 2008
· Bioorg. Med. Chem. Lett.
·
OSTI ID:1007629